Holen Sie sich die Stockscreener-App
12.96
2.99%
-0.40
Handel nachbörslich:
13.13
0.17
+1.31%
Schlusskurs vom Vortag:
$13.36
Offen:
$13.36
24-Stunden-Volumen:
604.16K
Relative Volume:
0.58
Marktkapitalisierung:
$680.66M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.878
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
+3.60%
1M Leistung:
+11.53%
6M Leistung:
+76.81%
1J Leistung:
+28.44%
1-Tages-Spanne:
$12.93
$13.53
1-Wochen-Bereich:
$12.35
$14.06
52-Wochen-Spanne:
$4.02
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
12.96 | 701.67M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
127.17 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.31 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.91 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.01 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
45.79 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Can Emergent BioSolutions Inc. stock rebound after recent weaknessMarket Volume Summary & Stock Timing and Entry Methods - ulpravda.ru
Emergent BioSolutions (EBS) Secures $21.5M U.S. Defense Order fo - GuruFocus
Emergent BioSolutions receives $21.5 million order from U.S. Department of War to supply Biothrax in 2026 - MarketScreener
Emergent BioSolutions Secures $21.5 Million Order for BioThrax® Anthrax Vaccine from U.S. Department of War - Quiver Quantitative
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026 - Yahoo Finance
Emergent BioSolutions partners with PANTHER on mpox treatment trial By Investing.com - Investing.com Canada
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa - The Manila Times
EBS (NYSE: EBS) insider files notice to sell 25,748 common shares - Stock Titan
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - The Manila Times
Emergent BioSolutions Inc. CEO Joe Papa to Present at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Emergent Biosolutions (NYSE:EBS) Reaches New 52-Week HighTime to Buy? - MarketBeat
Is Emergent BioSolutions Inc a good long term investmentEx-Dividend Date Alerts & Amplify Gains With Picks - earlytimes.in
Silver Oak Securities Incorporated Purchases New Position in Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent Biosolutions (NYSE:EBS) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
EBIT per share of Emergent BioSolutions Inc. – LSE:0IGA - TradingView — Track All Markets
Assenagon Asset Management S.A. Has $498,000 Stock Position in Emergent Biosolutions Inc. $EBS - MarketBeat
Emergent Biosolutions (NYSE:EBS) Stock Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Emergent BioSolutions Inc. (NYSE:EBS) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
EBS (NYSE: EBS) insider files Rule 144 to sell 104,695 shares - Stock Titan
Can Emergent BioSolutions Inc. stock beat analyst upgrades2025 Risk Factors & Reliable Entry Point Alerts - Улправда
How risky is Emergent BioSolutions Inc. stock nowJuly 2025 Pullbacks & Smart Money Movement Alerts - Улправда
Is Emergent BioSolutions Inc. stock recession proofEarnings Overview Summary & Real-Time Volume Analysis Alerts - Улправда
Is Emergent BioSolutions Inc. stock a buy before product launchesQuarterly Risk Review & Technical Analysis for Trade Confirmation - Улправда
Why Emergent BioSolutions Inc. stock is a must watch ticker2025 Support & Resistance & Free Weekly Watchlist of Top Performers - Улправда
Can Emergent BioSolutions Inc. stock survive global slowdownGlobal Markets & Consistent Income Trade Recommendations - Улправда
Institutional investors have a lot riding on Emergent BioSolutions Inc. (NYSE:EBS) with 73% ownership - simplywall.st
Earnings Risk: Will Emergent BioSolutions Inc. stock gain from government policiesMarket Growth Report & Risk Controlled Stock Pick Alerts - Улправда
Will Emergent BioSolutions Inc. stock profit from AI boom2025 Trade Ideas & Intraday High Probability Alerts - Улправда
Is Emergent BioSolutions Inc. (ER4) stock vulnerable to rate hikes2025 Year in Review & Safe Capital Growth Plans - DonanımHaber
What is the fair value of Emergent BioSolutions Inc. stock nowJuly 2025 Rallies & Smart Allocation Stock Reports - DonanımHaber
Is Emergent BioSolutions Inc. (ER4) stock a safe buy pre earningsWeekly Earnings Recap & AI Driven Stock Reports - DonanımHaber
How sustainable is Emergent BioSolutions Inc. stock dividend payoutStop Loss & Target Return Focused Stock Picks - Улправда
VP Lowry Surrenders 3,543 Of Emergent BioSolutions Inc [EBS] - TradingView — Track All Markets
Emergent BioSolutions (EBS) insider has shares withheld to cover taxes - Stock Titan
Emergent Biosolutions (NYSE:EBS) Earns Buy Rating from HC Wainwright - MarketBeat
EBS: HC Wainwright & Co. Reiterates Buy Rating and $15 Price Tar - GuruFocus
HC Wainwright & Co. Reiterates Emergent BioSolutions (EBS) Buy Recommendation - Nasdaq
Emergent Biosolutions (NYSE:EBS) Trading 5.9% HigherHere's Why - MarketBeat
Emergent BioSolutions Gains FDA Approval for Winnipeg Facility - The Globe and Mail
Energy Moves: Can Emergent BioSolutions Inc stock weather global recessionEarnings Growth Summary & Trade Opportunity Analysis Reports - moha.gov.vn
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site - The Manila Times
Emergent BioSolutions (NYSE: EBS) gains FDA OK for Winnipeg raxibacumab drug product site - Stock Titan
Emergent BioSolutions (NYSE: EBS) gains FDA approval for raxibacumab production - Stock Titan
Emergent BioSolutions Inc Stock Analysis and ForecastEvening Star Patterns & Low Risk Capital Growth Plans - earlytimes.in
Emergent Biosolutions (NYSE:EBS) Director Sells $263,148.48 in Stock - MarketBeat
Emergent BioSolutions (EBS) director reports option exercise and stock sales - Stock Titan
Emergent Biosolutions Q1 2025 Earnings Preview - MSN
EBS (NYSE: EBS) holder files Form 144 to sell 32,848 shares - Stock Titan
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):